Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Table 2 Ongoing and terminated passive immunotherapy clinical programs in Alzheimer’s disease

Name	Company	Phase	Trial population	Binding domain	Target
Solanezumab	Eli Lilly and Company	3	Prodromal and mild AD	Aβ_16–23	Soluble Aβ
Gantenerumab	Roche	2/3	Prodromal and mild AD	Combined Aβ N-terminal and mid domain, conformational	Aggregated Aβ
BAN2401	Eisai/ BioArctic Neuroscience/Eisai	2b	MCI due to AD or mild AD	N-terminal, conformational	Soluble Aβ protofibrils
Crenezumab	Genentech/Roche	2	Prodromal and mild/moderate AD	Aβ 12-23	Soluble oligomeric/fibrillar Aβ and plaque
Bapineuzumab	Elan/ Pfizer Inc./Johnson & Johnson	Intravenous and subcutaneous programs terminated	Mild/moderate AD	Aβ_1–5	Soluble and aggregated Aβ
BIIB037	Biogen Idec/Neuroimmune Therapeutics	1	MCI due to AD or mild AD	Conformational Aβ	Fibrillar Aβ
AAB003	Elan/Pfizer Inc./Janssen	1	Mild/moderate AD	Aβ_1–6	Soluble and aggregated Aβ
SAR228810	Sanofi	1	Mild/moderate AD	Not published	Soluble oligomeric/protofibrillar Aβ
ABP102	Abiogen Pharma	1	AD	Catalytic antibody cleaving Aβ	Aggregated Aβ
Ponezumab^a	Pfizer Inc.	1	Mild/moderate AD	Aβ_33–40	Soluble and aggregated Aβ

^aIn phase 2 in congophilic amyloid angiopathy. Aβ, amyloid-beta; AD, Alzheimer’s disease; MCI, mild cognitive impairment.

ISSN: 1758-9193